Page 116 - 2019_05-HaematologicaMondo-web

C. Michel et al.
106642); Deutsche José-Carreras Leukämiestiftung (DJCLS Roche, Grenzach- Wyhlen; and Essex, Munich, Germany. We H09/f, H06/04v, H03/01, R05/23, AH06.01); European thank E Matzat, R Pleil-Lösch, I Stalljann, G Bartsch, C
Union (LSHC-CT-2004–503216); Novartis Oncology, Nürnberg (Drs G Gerhard, S Schaffert, A Jacob and U Haus);
Sodan-Boyer, M Meckesheimer, U Böhm, A Gil and J Hehlmann for assistance.
References
1. Hehlmann R, Lauseker M, Saussele S, et al. Assessment of imatinib as first-line treat- ment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determi- nants. Leukemia. 2017;31(11):2398-2406.
2. Hochhaus A, Larson RA, Guilhot F, et al. Long-Term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917-927.
3. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016; 34(20):2333-2340.
4. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044-1054.
5. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus ima- tinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231- 237.
6. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
7. Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48-56.
8. Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with ima- tinib, predicts survival, and is achieved more quickly by optimized high-dose ima- tinib: results from the randomized CML- study IV. J Clin Oncol. 2014;32(5):415-423.
9. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, pre- viously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor opti- mization and selectivity study. J Clin Oncol. 2010;28(3):424-430.
10. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diag- nosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;
362(24):2260-2270.
11. Saglio G, Kim DW, Issaragrisil S, et al.
Nilotinib versus imatinib for newly diag- nosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-2259.
12. Saussele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remis- sion in chronic myeloid leukemia. Leukemia. 2016;30(8):1638-1647.
13. Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following front- line nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525-1531.
14. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommenda- tions for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016; 30(8):1648-1671.
15. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myel- ogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200-1206.
16. Hughes TP, Lipton JH, Spector N, et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014;124(5):729-736.
17. Gambacorti-Passerini C, Brummendorf TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intol- erance: Minimum 24-month follow-up. Am J Hematol. 2014;89(7):732-742.
18. Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important fac- tor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27(7):1511- 1519.
19. Guerin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromo- some positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014;30(11):2317-2328.
20. Flynn KE, Atallah E. Quality of life and long-term therapy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11(2):80-85.
21. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed
chronic myeloid leukemia. J Clin Oncol.
2011;29(12):1634-1642.
22. Hasford J, Pfirrmann M, Hehlmann R, et al.
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850-858.
23. Therneau TM, Grambsch PM. Modeling survival data: Extending the Cox model. New York: Springer, 2000.
24. Altmann DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "Optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86(11):829-835.
25. Davison AC, Hinkley DV. Bootstrap meth- ods and their application. Cambridge: Cambridge University Press, 1997.
26. Silverman B. Density estimation for statis- tics and data analysis. London: Chapman and Hall, 1986.
27. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicen- tre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-757.
28. Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4(7):e310-e316.
29. Fassoni AC, Baldow C, Roeder I, Glauche I. Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: A simu- lation study based on phase 3 trial data. Haematologica. 2018;103(11):1825-1834.
30. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treat- ment: the EUTOS score. Blood. 2011; 118(3):686-692.
31. Schutz C, Inselmann S, Sausslele S, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017; 31(4):829-836.
32. Inselmann S, Wang Y, Saussele S, et al. Development, function and clinical signifi- cance of plasmacytoid dendritic cells in chronic myeloid leukemia. Cancer Res. 2018;78(21):6223-6234.
962
haematologica | 2019; 104(5)